Carbamic acid compounds comprising a piperazine linkage as hdac inhibitors

A method for the treatment of a condition mediated by HDAC comprising administering to a subject suffering from a condition mediated by HDAC a therapeutically-effective amount of a compound of the formula:

• wherein:
• the piperazin-1,4-diyl group is optionally substituted;
• J1 is independently a covalent bond or —C(═O)—;
• J2 is independently —C(═O)— or —S(═O)2—;
• wherein:
• Cy is independently:
• C3-20carbocyclyl,
• C3-20heterocyclyl, or
• C5-20aryl;
• and is optionally substituted;
• Q1 is independently:
• a covalent bond;
• C1-7alkylene;
• or
• C1-7alkylene-X—C1-7alkylene, —X—C1-7alkylene, or C1-7alkylene-X—,
• wherein X is —O— or —S—;
• and is optionally substituted;
• Q2 is independently:
• C4-8alkylene;
• and is optionally substituted;
• and has a backbone length of at least 4 atoms;
• or:
• Q2 is independently:
• C5-20arylene-C1-7alkylene;
• C1-7alkylene-C5-20arylene;
• or,
• C1-7alkylene-C5-20arylene-C1-7alkylene;
• and is optionally substituted;
• and has a backbone length of at least 4 atoms;
• or a pharmaceutically acceptable salt, amide, ester, or ether thereof.